Therefore, further restricting the FGFR1 sequencing analysis to non-diffusely growing gliomas/MNGT tumors would yield 15% FGFR1 N546/K656 mutant cases after exclusion of cases with BRAF fusion, IDH1/2, NF1 or TERT mutation. This evidence concerns the gene BRAF and central nervous system cancer.